Business Context and Reporting Period
Jasper Therapeutics, Inc. filed this Form 8-K to report the results of its December 15, 2023 Special Meeting of Stockholders. The filing is a corporate-governance update and does not provide operating or financial results.
Financial and Liquidity Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash, liquidity, or other financial metrics.
Material Changes and Meeting Results
- As of the November 15, 2023 record date, 111,575,261 shares of common stock were outstanding.
- Holders representing 92,015,007 shares, or approximately 82% of the outstanding common stock, were represented at the meeting.
- Stockholders approved an amendment authorizing the Board, in its sole discretion and on or before December 15, 2024, to effect a reverse stock split at a ratio between 1-for-3 and 1-for-10, or any ratio in between.
- The reverse stock split may be completed without reducing the authorized number of common shares and without further stockholder approval.
- Reverse stock split proposal: 91,108,798 votes for, 873,917 against, and 32,292 abstentions.
- Stockholders also approved a potential meeting adjournment to solicit additional proxies. The proposal received 91,306,235 votes for, 669,886 against, and 38,886 abstentions.
- An adjournment was not necessary because sufficient votes were received to approve the reverse stock split proposal.
Guidance, Outlook, Risks and Unusual Items
- The Board has discretion regarding whether to implement the reverse stock split, its timing, and the final ratio through December 15, 2024; approval does not establish that a split will occur.
- If implemented, a reverse stock split would reduce the number of outstanding shares proportionally, subject to the final ratio and any treatment of fractional shares, which are not specified in this filing.
- The filing does not provide management guidance, clinical or commercial outlook, financing plans, or updated risk disclosures.
Key Facts for Investors to Verify
- Whether and when the Board authorizes the reverse stock split.
- The final reverse stock split ratio, if implemented.
- Any subsequent filing describing the effective date, treatment of fractional shares, and resulting share counts.
- Separate financial filings for Jasper Therapeutics’ cash position, financing needs, operating losses, and going-concern or liquidity risks.